{"url":"https://lda.senate.gov/api/v1/filings/2fbf16bc-5aa1-4fd5-a556-e85addb4a2f2/","filing_uuid":"2fbf16bc-5aa1-4fd5-a556-e85addb4a2f2","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2023,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/2fbf16bc-5aa1-4fd5-a556-e85addb4a2f2/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Minor, Partner","dt_posted":"2023-10-20T11:00:01-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 8th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":76855,"url":"https://lda.senate.gov/api/v1/registrants/76855/","house_registrant_id":32113,"name":"DLA PIPER LLP (US)","description":"Law firm.","address_1":"500 8th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MINOR","contact_telephone":"+1 202-799-4312","dt_updated":"2026-01-29T14:20:14.358284-05:00"},"client":{"id":53491,"url":"https://lda.senate.gov/api/v1/clients/53491/","client_id":53491,"name":"BIOHAVEN PHARMACEUTICALS, INC.","general_description":"A biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"CT","state_display":"Connecticut","country":"US","country_display":"United States of America","ppb_state":"CT","ppb_state_display":"Connecticut","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-11-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139175,"prefix":"mr","prefix_display":"MR.","first_name":"JAMIE","nickname":null,"middle_name":"ALEXEI","last_name":"GREGORIAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101694,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"PINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139476,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"GREENWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}